Administration of RAS Inhibitor before the Onset of Diabetic Nephropathy Counteracts the Adverse Effect of Chronic Hyperglycemia and Reduces the Augmentation of Urinary Albumin Excretion: A Retrospective Clinical Study

Table 1

Association between the alteration of urinary albumin excretion and various clinical parameters: univariate analysis.

	Control group		RAS inhibitor group
HbA1c, annual mean	0.406	<0.0005	0.003	n.s.
Age, baseline	−0.083	n.s.	0.146	n.s.
Duration of diabetes, baseline	−0.002	n.s.	−0.104	n.s.
Systolic BP, annual mean	0.021	n.s.	0.250	n.s.
Diastolic BP, annual mean	0.041	n.s.	−0.004	n.s.
CRP, annual mean	0.199	n.s.	−0.090	n.s.
TG, annual mean	0.093	n.s.	0.069	n.s.
HDL-C, annual mean	−0.146	n.s.	−0.083	n.s.
LDL-C, annual mean	−0.031	n.s.	0.101	n.s.
BMI annual mean	0.035	n.s.	−0.033	n.s.
eGFR, baseline	0.202	n.s.	0.066	n.s.

Abbreviations: n.s., not significant; BP, blood pressure; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index; RAS, renin-angiotensin system.